Phase 3 N=500 A Six-Week Safety Study of an Investigational Ophthalmic Solution
Allergic Conjunctivitis
Primary: Adverse Events — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=30 Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Glaucoma · Ocular Hypertension
Primary: Cmax of Carteolol — 0.8558; 0.9984; 1.174; 1.627 ng/mL
Phase 2 N=87 H-1337 Ophthalmic Solution Phase 1/2
Glaucoma, Open-Angle
Primary: Intraocular Pressure (IOP) — -4.45; -5.16; -4.93; -0.39 mm Hg
Phase 3 N=516 A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
Healthy Subjects
Primary: Tolerability of AC 170 0.24% at Visit 1 (Day 1) — 0.87; 0.50; 0.64; 0.42 units on a scale
Phase 3 N=1,454 Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Dry Eye Syndrome
Primary: Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7 — 4.9; 4.8; -0.8; -0.7 Units on a scale
Phase 1 N=29 Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201
Myopia
Primary: Number of Unexpected Adverse Events — 41 adverse events
N/A N=32 Optive Brand For Day And Night Dry Eye Management
Dry Eye
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score — -12.85 Scores on a scale — p=.001
Phase 3 N=249 A Safety Study of of AG-920 Sterile Topical Ophthalmic Solution
Anesthesia, Local
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 40; 13 Participants
N/A N=20 Tear Film Stability After Instillation of Over-the-Counter (OTC) Artificial Drops
Dry Eye Disease
Primary: Aqueous Tear Evaporation Rate Before and After Use of OTC Artificial Tears — 0.047; 0.049; 0.031; 0.032 (µl/cm2/min)
Phase 1 N=90 Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
Acanthamoeba Keratitis
Primary: Number of Subjects With Dose-limiting Adverse Events — 0; 2; 3; 0 participants
Phase 2 N=141 Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Dry Eye
Primary: Change in Ocular Surface Disease Index (OSDI) — 25.8; 25.8; 24.8; 12.8 score on a scale
Phase 1 N=100 Safety Study of OPC-12759 Ophthalmic Solution
Dry Eye Syndromes
Primary: Number of Subjects With Blurred Vision After Instillation — 0; 10; 0; 21 participants
Phase 4 N=50 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan
Allergic Conjunctivitis
Primary: Mean Ocular Itching at 7 Minutes Post-CAC, Day 1 — 0.23; 0.37 units on a scale
Phase 1 N=22 Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Safety · Tolerability · Ocular Surface
Primary: Incidence of Related Unexpected Adverse Events (AE) — 12 Number of unexpected related AE
Phase 1 N=34 Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution
Dry Eye
Primary: Presence of Adverse Events (AEs) — 7; 8 Participants — p=0.409
N/A N=28 Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye Discomfort
Ocular Dryness
Primary: Tear Film Break-up Time With Fluorescein (TFBUT) — 5.00; 13.46 Second
Phase 3 N=209 Confirmatory Study of OPC-12759 Ophthalmic Solution
Dry Eye
Primary: Change in Fluorescein Corneal Staining (FCS) Score From Baseline — -3.3; -2.0; -2.9 score on a scale — p=<0.001
Phase 3 N=166 DE-111 Against Timolol Ophthalmic Solution 0.5%
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal IOP (Intraocular Pressure) at End of Study — -3.2; -1.7 mmHg — p=< 0.001
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 3 N=156 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 36; 23 participants
N/A N=350 Comparative Performance of a Bausch & Lomb Multipurpose Solution and Alcon OptiFree Replenish Multipurpose Solution
Adverse Effect of Contact Lens Solution
Primary: Subjective Assessment of Comfort and Cleanliness — 89.71; 89.26; 87.45; 86.63 Scores on a scale
N/A N=295 Vistakon Investigational Multi-purpose Contact Lens Care Solution.
Contact Lens Wear
Primary: Slit Lamp Findings (SLF) — 0; 0; 0; 0 eyes (2 per subject)
Phase 3 N=126 Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Cataract
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 28; 20 Participants
Phase 2 N=568 Efficacy and Safety of Bromfenac Ophthalmic Solution
Cataract Surgery
Primary: Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero — 157; 164 Participant
N/A N=121 OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers
Presbyopia
Primary: Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score at Day 30 — 13.4; 15.8 units on a scale — p==0.0030
N/A N=300 Investigational Multi-purpose Contact Lens Care Solution.
Contact Lens Wear
Primary: Slit Lamp Findings — 11; 16; 0; 0 Subjects Eyes
Phase 2 N=256 Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Inflammation · Pain · Cataract
Primary: Proportion of Subjects With Clearing of Anterior Inflammation — 18; 18; 13 Participants
N/A N=372 Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)
Cataract
Primary: Percent Change in Mean Epithelial Cell Density (ECD) — -8.4; -6.8 percentage change in ECD
Phase 2 N=30 Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome
Dry Eye Syndrome
Primary: Tear Film Break-up Time (TBUT) — 5.2; 4.7; 6.1; 7.3 seconds
Phase 2 N=164 Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)] at Day 7 — -2.8; -4.7; -8.1; -4.5 hours x units on a scale